About the Company
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CCXI News
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...
Immuneering Corporation (IMRX)
CEO and Founder of ChemoCentryx, Inc.CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and ...
Ocwen Financial Stock (NYSE:OCN), Quotes and News Summary
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per ...
Inflation Problems Persist And AI Makes Headlines: Forbes AI Newsletter - September 17th
Earnings per share have grown 11.68% over the past 12 months. Chemocentryx Inc – The biotech company is one of our Top Shorts for next month with our AI rating them an F in our Low Momentum ...
Federal Reserve Continues Interest Rate Hikes And Housing Market Sees Spike In Mortgage Rates: Forbes AI Newsletter - September 24th
Earnings per share have grown 8.78% over the past 12 months. Chemocentryx Inc (CCXI) – The biotech company remains one of our Top Shorts for next month with our AI rating them an F in our Low ...
Global Neovascular Age-Related Macular Degeneration Treatment Market Poised for Significant Growth, Expected to Reach US$ 4.89 Billion by 2033
According to a new market research report published by Future Market Insights, the global neovascular age-related macular degeneration treatment market is projected to experience a robust growth rate ...
Plc Gsk's Net Worth
Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
Snap Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
MPW Medical Properties Trust, Inc.
Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama ...
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
Prior to MyoKardia, he served as Chief Operating Officer at ChemoCentryx, Inc. and held several positions of increasing responsibility at Actelion Pharmaceuticals, including serving as President ...
Loading the latest forecasts...